{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Leukemia%2C+Chronic+Lymphatic&page=46", "query": { "condition": "Leukemia, Chronic Lymphatic", "page": 46 }, "page_size": 10 }, "pagination": { "page": 46, "page_size": 10, "total_count": 2416, "total_pages": 242, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Leukemia%2C+Chronic+Lymphatic&page=47&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Leukemia%2C+Chronic+Lymphatic&page=45&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T10:52:42.812Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02566395", "title": "Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Acute Myelogenous Leukemia", "Myelodysplastic Syndrome", "Chronic Myelogenous Leukemia", "Non-Hodgkin Lymphoma", "Hodgkin Lymphoma" ], "interventions": [ { "name": "Radiation", "type": "RADIATION" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Donor Lymphocyte Infusion (DLI)", "type": "BIOLOGICAL" }, { "name": "Haploidentical Stem Cell Transplantation", "type": "BIOLOGICAL" } ], "intervention_types": [ "RADIATION", "DRUG", "BIOLOGICAL" ], "sponsor": "Northwell Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "2 Years to 21 Years" }, "enrollment_count": 10, "start_date": "2014-12", "completion_date": "2022-02-14", "has_results": false, "last_update_posted_date": "2022-04-07", "last_synced_at": "2026-10-20T10:52:42.812Z", "location_count": 1, "location_summary": "New Hyde Park, New York", "locations": [ { "city": "New Hyde Park", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02566395" }, { "nct_id": "NCT00298987", "title": "A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia, Myeloid, Chronic", "Leukemia, Lymphocytic, Acute, L2" ], "interventions": [ { "name": "Dasatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2006-02", "completion_date": "2007-06", "has_results": false, "last_update_posted_date": "2010-02-08", "last_synced_at": "2026-10-20T10:52:42.812Z", "location_count": 30, "location_summary": "Corona, California • Aurora, Colorado • Colorado Springs, Colorado + 27 more", "locations": [ { "city": "Corona", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Waterford", "state": "Connecticut" }, { "city": "Daytona Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00298987" }, { "nct_id": "NCT00039416", "title": "Imatinib Mesylate in Treating Patients With Myelofibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Myelomonocytic Leukemia", "Essential Thrombocythemia", "Polycythemia Vera", "Primary Myelofibrosis" ], "interventions": [ { "name": "imatinib mesylate", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2002-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-02-25", "last_synced_at": "2026-10-20T10:52:42.812Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00039416" }, { "nct_id": "NCT00899496", "title": "Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer" ], "interventions": [ { "name": "immunological diagnostic method", "type": "OTHER" }, { "name": "physiologic testing", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": "120 Years", "sex": "ALL", "summary": "Up to 120 Years" }, "enrollment_count": 54, "start_date": "2005-09", "completion_date": "2009-10-23", "has_results": false, "last_update_posted_date": "2017-05-30", "last_synced_at": "2026-10-20T10:52:42.812Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00899496" }, { "nct_id": "NCT00513318", "title": "Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients Wtih Advanced Hematopoietic Malignancies", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Acute Myeloid Leukemia", "Myelodysplasia", "Acute Lymphoblastic Leukemia", "Chronic Myelogenous Leukemia", "Multiple Myeloma", "Lymphomas", "Low-grade NHL and Chronic Lymphocytic Leukemia" ], "interventions": [], "intervention_types": [], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 15, "start_date": "2004-08", "completion_date": "2009-06", "has_results": false, "last_update_posted_date": "2013-08-02", "last_synced_at": "2026-10-20T10:52:42.812Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00513318" }, { "nct_id": "NCT00003694", "title": "Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Chronic Phase Chronic Myelogenous Leukemia" ], "interventions": [ { "name": "omacetaxine mepesuccinate", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 60, "start_date": "1999-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-05", "last_synced_at": "2026-10-20T10:52:42.812Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003694" }, { "nct_id": "NCT02367456", "title": "A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myelodysplastic Syndrome", "Acute Myeloid Leukemia", "Chronic Myelomonocytic Leukemia" ], "interventions": [ { "name": "PF-04449913 (Glasdegib)", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 73, "start_date": "2015-04-28", "completion_date": "2022-03-07", "has_results": true, "last_update_posted_date": "2024-01-19", "last_synced_at": "2026-10-20T10:52:42.812Z", "location_count": 21, "location_summary": "Birmingham, Alabama • La Jolla, California • New Haven, Connecticut + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02367456" }, { "nct_id": "NCT01093586", "title": "Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome", "Adult Acute Lymphoblastic Leukemia in Remission", "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", "Adult Acute Monoblastic Leukemia (M5a)", "Adult Acute Monocytic Leukemia (M5b)", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Erythroleukemia (M6a)", "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Adult Pure Erythroid Leukemia (M6b)", "B-cell Adult Acute Lymphoblastic Leukemia", "B-cell Childhood Acute Lymphoblastic Leukemia", "Blastic Phase Chronic Myelogenous Leukemia", "Burkitt Lymphoma", "Childhood Acute Erythroleukemia (M6)", "Childhood Acute Lymphoblastic Leukemia in Remission", "Childhood Acute Megakaryocytic Leukemia (M7)", "Childhood Acute Minimally Differentiated Myeloid Leukemia (M0)", "Childhood Acute Monoblastic Leukemia (M5a)", "Childhood Acute Monocytic Leukemia (M5b)", "Childhood Acute Myeloid Leukemia in Remission", "Childhood Chronic Myelogenous Leukemia", "Childhood Diffuse Large Cell Lymphoma", "Childhood Immunoblastic Large Cell Lymphoma", "Childhood Myelodysplastic Syndromes", "Childhood Nasal Type Extranodal NK/T-cell Lymphoma", "Chronic Myelomonocytic Leukemia", "Chronic Phase Chronic Myelogenous Leukemia", "Cutaneous B-cell Non-Hodgkin Lymphoma", "de Novo Myelodysplastic Syndromes", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Juvenile Myelomonocytic Leukemia", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Nodal Marginal Zone B-cell Lymphoma", "Previously Treated Myelodysplastic Syndromes", "Prolymphocytic Leukemia", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Anaplastic Large Cell Lymphoma", "Recurrent Childhood Grade III Lymphomatoid Granulomatosis", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Relapsing Chronic Myelogenous Leukemia", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndromes", "Secondary Myelofibrosis", "Splenic Marginal Zone Lymphoma", "Stage I Chronic Lymphocytic Leukemia", "Stage II Chronic Lymphocytic Leukemia", "Stage III Chronic Lymphocytic Leukemia", "Stage IV Chronic Lymphocytic Leukemia", "T-cell Adult Acute Lymphoblastic Leukemia", "T-cell Childhood Acute Lymphoblastic Leukemia", "T-cell Large Granular Lymphocyte Leukemia", "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "double-unit umbilical cord blood transplantation", "type": "PROCEDURE" }, { "name": "cytogenetic analysis", "type": "OTHER" }, { "name": "bone marrow aspiration", "type": "PROCEDURE" }, { "name": "fluorescence in situ hybridization", "type": "OTHER" }, { "name": "busulfan", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "anti-thymocyte globulin", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "flow cytometry", "type": "OTHER" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "OTHER", "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "12 Years to 64 Years" }, "enrollment_count": 14, "start_date": "2007-09", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2019-01-23", "last_synced_at": "2026-10-20T10:52:42.812Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01093586" }, { "nct_id": "NCT01995669", "title": "Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Grade 3a Follicular Lymphoma", "Recurrent Follicular Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Small Lymphocytic Lymphoma", "Refractory Follicular Lymphoma", "Refractory Marginal Zone Lymphoma", "Refractory Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2014-05-27", "completion_date": "2023-01-23", "has_results": true, "last_update_posted_date": "2025-06-24", "last_synced_at": "2026-10-20T10:52:42.812Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01995669" }, { "nct_id": "NCT03615105", "title": "Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphoid Leukemia (ALL)", "Acute Myeloid Leukemia (AML)", "Chronic Myeloid Leukemia (CML)", "Hodgkin Lymphoma", "Non-Hodgkin Lymphoma", "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Hyperfractionated total body irradiation", "type": "RADIATION" }, { "name": "Thiotepa", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Clofarabine", "type": "DRUG" }, { "name": "HPC(A) stem cell allograft", "type": "PROCEDURE" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Rabbit antithymocyte globulin", "type": "DEVICE" } ], "intervention_types": [ "RADIATION", "DRUG", "PROCEDURE", "DEVICE" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "65 Years", "sex": "ALL", "summary": "Up to 65 Years" }, "enrollment_count": 9, "start_date": "2018-07-25", "completion_date": "2024-03-06", "has_results": true, "last_update_posted_date": "2025-04-06", "last_synced_at": "2026-10-20T10:52:42.812Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03615105" } ] }